[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610588":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":24,"interventions":35,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":43,"collaborators":11,"id":45,"slug":11,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":11,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":11,"enrollmentInfo":53,"targetDuration":11,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":11,"overallStatus":62,"whyStopped":11,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":11},{"fullName":5,"class":6},"Dong-A ST Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Change from baseline of HbA1c(%)",null,"24 weeks",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":19},"QUADRUPLE",[20,21,22,23],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[25,30],{"label":26,"type":27,"description":11,"interventionNames":28},"DA-5218","EXPERIMENTAL",[29],"Drug: DA-5218",{"label":31,"type":32,"description":11,"interventionNames":33},"DA-5218-C","ACTIVE_COMPARATOR",[34],"Drug: DA-5218-C",[36,40],{"type":37,"name":26,"description":38,"armGroupLabels":39,"otherNames":11},"DRUG","DA-5218 + DA-5218-C placebo",[26],{"type":37,"name":31,"description":41,"armGroupLabels":42,"otherNames":11},"DA-5218-C + DA-5218 placebo",[31],{"type":44,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610588",false,"NCT07229534","Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes","A Phase IV Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes Inadequately Controlled With Metformin","Inclusion Criteria:\n\n* 7.0%≤HbA1c≤10.5% and fasting glucose≤270mg\u002FdL\n* Treated with 1,000mg\u002Fday dose of metformin for at least 8 weeks\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus\n* eGFR\\\u003C45mL\u002Fmin\u002F1.73m2\n* ALT and AST 3 times or higher than upper normal range\n* Determined by investigator as unfit to participate in a clinical trial due to other reasons","ALL","19 Years",{"count":54,"type":55},238,"ESTIMATED","INTERVENTIONAL",[58],"PHASE4","This study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-5218 in patients with type 2 diabetes who have inadequate glycemic control with metformin",[61],"Diabete Mellitus","NOT_YET_RECRUITING","2025-11-13",{"date":65,"type":66},"2025-11-17","ACTUAL",{"date":68,"type":55},"2025-11",{"date":70,"type":55},"2027-11",{"name":5,"class":6}]